NASDAQ$HUMA
Humacyte Inc · Q2 2022 earnings
Q2 2022 earnings · · Investor relations
Briefing
Announced financial results for the second quarter ended June 30, 2022, and highlighted recent corporate accomplishments.
Humacyte reported revenue of $1.3 million for the second quarter of 2022, compared to $0.7 million for the second quarter of 2021. Net income was $36.9 million for the second quarter of 2022, compared to a net loss of $17.2 million for the second quarter of 2021. The company's cash, cash equivalents and short-term investments totaled $189.0 million as of June 30, 2022.
- HAVs successfully implanted in wounded Ukrainian citizens and reported to be functioning, saving limbs
- Hosted key opinion leader (KOL) webinar on HAV in the treatment of vascular trauma, featuring Ernest E. Moore, M.D and Gregory A. Magee, M.D.
- Strengthened Board of Directors with appointment of Diane Seimetz, Ph.D. and leadership team with appointment of Shamik Parikh, M.D. as Chief Medical Officer
- Multiple scientific meeting presentations and publications highlighting clinical HAV data in vascular trauma and arteriovenous access and preclinical small-diameter HAV data in coronary artery bypass grafting (CABG)
Headline financials
Revenue & EPS history
Humacyte · Revenue · Quarterly
$1.3M
Forward guidance
Humacyte believes that its cash, cash equivalents and short-term investments are adequate to fund operations through 2024, past the Company’s current expected timeline for potential approval of the HAV in vascular trauma.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q2 2022
+5.1%
Avg return
Earnings day
+2.0%
Avg return
5 days after
+3.5%
Avg return
30 days after
62%
13 / 21 earnings
Positive
+37.0%
Q2 2023
Best reaction
-30.1%
Q2 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +22.9% | -1.5% | +15.2% | |
| Q4 2025 | -15.1% | -25.1% | -33.0% | |
| Q3 2025 | -3.2% | -11.7% | +2.3% | |
| Q2 2025 | -30.1% | -24.2% | -40.3% | |
| Q1 2025 | +19.5% | +23.8% | +25.4% | |
| Q4 2024 | -2.5% | -27.4% | -28.4% | |
| Q3 2024 | +4.9% | +1.5% | -8.2% | |
| Q1 2024 | +21.2% | +43.1% | +60.8% | |
| Q4 2023 | -12.8% | -13.9% | +2.8% | |
| Q3 2023 | +7.3% | +9.1% | +27.9% | |
| Q2 2023 | +37.0% | +8.9% | +19.0% | |
| Q1 2023 | -6.1% | -2.5% | +1.1% | |
| Q4 2022 | +4.9% | -1.3% | +7.1% | |
| Q3 2022 | +2.2% | -5.4% | -4.5% | |
| Q2 2022 | +8.6% | +9.1% | +2.5% | |
| Q1 2022 | -9.5% | -12.7% | -18.8% | |
| Q4 2021 | +14.1% | +12.2% | +16.5% | |
| Q2 2021 | +14.1% | +12.2% | +16.5% | |
| Q3 2021 | +9.0% | +18.4% | +4.0% | |
| Q1 2021 | +0.0% | +0.0% | +4.9% | |
| Q4 2020 | +21.2% | +28.4% | +1.5% | |
| Q3 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro